This company has been acquired
Resumen de acción TCRR
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de TCR2 Therapeutics Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.48 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$0.82 |
| Beta | 1.93 |
| 1 Month Change | -21.28% |
| 3 Month Change | 22.31% |
| 1 Year Change | -38.59% |
| 3 Year Change | -88.47% |
| 5 Year Change | n/a |
| Change since IPO | -90.18% |
Noticias y actualizaciones recientes
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Rentabilidad de los accionistas
| TCRR | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -6.3% | 4.4% | 0.6% |
| 1Y | -38.6% | 2.8% | 23.9% |
Rentabilidad vs. Industria: TCRR underperformed the US Biotechs industry which returned 12.2% over the past year.
Rentabilidad vs. Mercado: TCRR underperformed the US Market which returned 2.4% over the past year.
Volatilidad de los precios
| TCRR volatility | |
|---|---|
| TCRR Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: TCRR's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: TCRR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 58 | Garry Menzel | www.tcr2.com |
Resumen de fundamentos de TCR2 Therapeutics Inc.
| Estadísticas fundamentales de TCRR | |
|---|---|
| Capitalización bursátil | US$58.11m |
| Beneficios(TTM) | -US$163.10m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está TCRR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TCRR | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$163.10m |
| Beneficios | -US$163.10m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.15 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado TCRR a largo plazo?
Ver rendimiento histórico y comparativa